Rights, claims and consumer protection
KITIMI.

LifeStyle

Is It Legal to Buy Prescription Drugs From Canada?

For most U.S. residents, the short answer is generally no under federal law—even when the medicine is legal in Canada and the buyer has a valid U.S. prescription. A different answer sometimes appears online because the Food and Drug Administration may use enforcement discretion for certain small personal-use shipments. Discretion is not the same as legal authorization, and it does not guarantee that a parcel will be admitted.

This page describes the federal position as of September 21, 2026. It separates three concepts that are often blended together: the statutory rule, FDA enforcement discretion, and FDA-authorized Section 804 programs.

The federal rule

The FDA says foreign drugs are generally unapproved in the United States even if another country has approved them. Importing an unapproved drug violates federal law. Other problems may also arise if a product lacks FDA-compliant labeling or is dispensed outside the authorized U.S. supply chain.

The place of manufacture does not settle the issue. A tablet made in the same facility as a U.S. product may still be a different regulated product because its approval, labeling, packaging, supply chain, or National Drug Code differs. A valid prescription likewise does not automatically make importation lawful.

Controlled substances require special caution. The Drug Enforcement Administration, rather than the FDA alone, generally decides whether a controlled substance may be imported. Travelers and mail-order buyers should not assume the FDA personal-importation factors override DEA rules.

What FDA enforcement discretion means

The FDA’s Personal Importation page says agency personnel may consider a more permissive decision in limited circumstances. For a prescription product used for a serious condition, the stated considerations include:

  • effective treatment may not be available domestically through commercial or clinical means;
  • the product is not commercially promoted to U.S. residents;
  • it does not present an unreasonable risk;
  • the consumer affirms in writing that it is for personal use; and
  • the quantity is generally no more than a three-month supply, with a U.S.-licensed doctor’s name and address or evidence that treatment began abroad.

These are considerations, not a safe harbor. The FDA also states that personal importation creates no right or expectation that an unapproved drug will be allowed into the country. A shipment can be detained, refused, or destroyed. Customs and FDA reviewers assess admissibility at the border.

The often-repeated phrase “90-day rule” is therefore misleading. Ninety days is normally an upper quantity consideration within a discretionary policy; it is not a blanket permission to order any three-month supply from any Canadian website. Price savings alone do not appear among the FDA’s stated criteria for a serious-condition import.

Why many parcels have nevertheless arrived

Enforcement practice and legal status are different questions. Limited agency resources, risk-based screening, and the facts of an individual parcel can affect what is examined or admitted. A buyer whose previous packages arrived has evidence of delivery, not a legal authorization for the next order.

Likewise, a pharmacy’s willingness to ship does not decide U.S. admissibility. Canadian licensing governs the pharmacy’s conduct in Canada; U.S. federal authorities govern entry into the United States. Both sets of rules can matter at once.

Congress created a structured pathway for importing certain Canadian prescription drugs through Section 804 of the Federal Food, Drug, and Cosmetic Act. FDA regulations permit time-limited Section 804 Importation Programs, or SIPs, sponsored by states or Indian tribes. These are controlled, wholesale programs—not permission for an individual to place a retail order online.

An authorized SIP must identify eligible drugs, use an authorized importer, test products, relabel them for the U.S. market, preserve supply-chain integrity, report adverse events, and demonstrate significant consumer savings without additional public-health risk. Several categories are excluded, including controlled substances, biological products and certain injected or REMS drugs.

The FDA authorized Florida’s proposal in January 2024 and granted it a series of implementation-deadline extensions, most recently through May 6, 2026. As of September 21, 2026, that deadline has passed and no further extension has been publicly confirmed. Florida has not shipped any drugs under the program: a 2026 state contract to run it drew no bidders, and the program remains stalled despite tens of millions of dollars spent on infrastructure, including an unused warehouse. Authorization is an important legal milestone, but it is not equivalent to a resident ordering from a Canadian pharmacy, and an authorized program that has not shipped anything provides no working example of a legal personal-import route yet.

As of September 21, 2026, an FDA-authorized Section 804 program remains, on paper, the clearest lawful pathway discussed here — but Florida’s program, the only one authorized so far, has not actually moved drugs. It does not convert ordinary personal mail orders into SIP shipments either way. Check the FDA’s Section 804 program page for the current status before relying on this pathway.

Travel across the border is not an automatic exception

Carrying medicine in luggage can involve different inspection circumstances, but it does not erase federal drug law. Foreign nationals visiting the United States receive distinct FDA guidance and may generally bring or ship a 90-day supply with documentation. That specific language should not be repurposed as a general entitlement for U.S. citizens or permanent residents.

Anyone traveling with medicine should keep it in its original container, carry the prescription and clinician information, and check FDA, CBP and DEA rules before travel. State rules and airline security requirements may add separate constraints.

What to check before making a decision

  1. Ask the prescriber whether an FDA-approved U.S. alternative, generic, assistance program or different dosage is available.
  2. Read the FDA personal-importation criteria rather than relying on a seller’s summary.
  3. Determine whether the product is controlled, biological, temperature-sensitive or otherwise high risk.
  4. Confirm the pharmacy’s credentials independently; see how to verify a legitimate Canadian online pharmacy.
  5. Ask the insurer in writing whether an out-of-network foreign purchase is eligible. See insurance coverage for Canadian prescription purchases.
  6. Do not stop or ration treatment while waiting for an international parcel.

The October 2026 postal-entry changes are a separate customs issue. They do not rewrite the underlying FDA standard. See what Canadian pharmacies say may happen to U.S. shipments for the official rule and the industry’s interpretation.

What can happen when a shipment is reviewed

FDA and CBP do not need to treat every parcel identically. A reviewer may examine the declaration, sender, product, quantity, labeling and supporting records. A parcel that appears to contain an unapproved, misbranded or otherwise noncompliant drug may be detained. The recipient can receive a notice explaining the apparent violation and the available response procedure. Depending on the facts and applicable authority, the final result may be release, refusal, return or destruction.

This process is another reason not to describe personal importation as “legal because customs usually lets it through.” A package may pass without examination, receive a discretionary decision, or be refused. None of those individual outcomes changes the statute for everyone else. Delivery history is also a poor basis for treatment planning: a later parcel may take longer or receive a different decision.

Consumers should preserve the original prescription, invoice, product information and correspondence. If a detention notice arrives, read its deadline and instructions rather than sending informal explanations to an unrelated office. An attorney experienced in FDA or customs law may be appropriate when the medicine is costly, the facts are unusual or the notice alleges more than a routine admissibility problem.

Personal use is not commercial importation

Ordering for oneself is different from reselling, distributing or ordering on behalf of multiple people. Large quantities, repeated shipments, inconsistent names or commercial promotion can undermine a claim that a parcel is solely for personal treatment. The FDA’s published considerations do not protect a side business or a group-buying arrangement.

The identity of the product matters as much as quantity. Medicines with special safety controls, counterfeit risk, cold-chain requirements or controlled-substance status can raise issues that a simple “three-month supply” slogan ignores. A buyer should never split orders or misdescribe contents to avoid review. False customs declarations can create separate legal problems.

Frequently Asked Questions

Not automatically. A prescription supports medical need but does not turn a foreign unapproved product into an FDA-approved import.

Is a 90-day supply always allowed?

No. Quantity is only one factor in a discretionary FDA policy. The product, condition, risk, promotion to U.S. residents and supporting documentation also matter.

Canadian licensure is an important safety credential, but it does not itself authorize U.S. importation. Pharmacy legitimacy and shipment admissibility are separate questions.

Can the government seize my package?

FDA and CBP may detain or refuse products that appear noncompliant. FDA procedures generally provide notice and an opportunity to respond before refusal or destruction, subject to the applicable process.

Is Florida’s program available to individual online shoppers?

No. Florida’s SIP is a state-sponsored wholesale pathway with approved participants, drugs, testing and labeling. It is not a retail mail-order exception.

No. Enforcement discretion describes how an agency may prioritize or handle a violation. It does not amend the statute or confer an enforceable right.

Has Congress legalized personal importation in 2026?

No. S.641, the Safe and Affordable Drugs from Canada Act of 2025, remained a pending bill as of September 21, 2026. A proposal does not change current law unless Congress passes it and it becomes law.

Primary sources

This page provides general information as of September 21, 2026. It is not legal or medical advice. Rules, agency practices and program status can change; consult the relevant agency or a qualified professional for current guidance about a specific situation.